首页|猪瘟弱毒标记疫苗候选株RecC-M1垂直传播可能性评价

猪瘟弱毒标记疫苗候选株RecC-M1垂直传播可能性评价

扫码查看
为探究猪瘟病毒(CSFV)弱毒标记疫苗候选株RecC-M1在猪群中的垂直传播能力,采用二次免疫方案,以5.0×103.5TCID50的RecC-M1经颈部肌肉注射接种12头后备母猪,另从试验猪场随机挑选20头按常规免疫程序以750 RID剂量给后备母猪接种猪瘟弱毒C株疫苗作为对照.接种后观察试验母猪临床症状并记录其产仔情况;首免后3、5、7、14 d采集母猪鼻拭子和肛拭子样品,并于母猪妊娠中期和分娩当日进行尾静脉采血,qPCR检测各组猪的病毒血症及排毒情况,ELISA检测猪血清中分别针对BVDV1和CSFV相应抗原的抗体水平;所有接种RecC-M1的母猪在生产当天留取2头新生仔猪(共24头)并在其吮吸初乳前安乐死后剖检,观察主要脏器大体病变情况,采集扁桃体、淋巴结、脾脏和膀胱组织用于组织病理学观察,血液样品用于猪瘟病毒抗体和核酸检测.结果表明,所有母猪免疫后均未出现临床症状,接种后2周内的拭子样品中未检测到病毒核酸,妊娠中期和分娩时血清中的RecC-M1 E2和BVDV1-Erns特异性抗体均维持在较高水平,RecC-M1接种母猪的胎均仔数、死胎数和弱仔数与对照组无显著差异.对RecC-M1接种母猪所产24头新生仔猪的剖检发现,扁桃体、淋巴结、脾脏、肾脏和膀胱均未见出血、肿大等病变;组织学结果显示,扁桃体、淋巴结、脾脏和肾脏的组织结构正常,均未见有出血性变化;仔猪血样和组织样品均无病毒核酸检出,亦未见抗体阳性.结果表明,CSFV弱毒标记疫苗候选株RecC-M1对母猪及仔猪都是安全的,不发生病毒的垂直传播,为该疫苗后选株的产业化开发奠定了基础.
Evaluation of Vertical Transmission Potential of An Attenuated Classical Swine Fever Virus Marker Vaccine Candidate RecC-M1
To investigate the vertical transmission potential of an attenuated classical swine fever virus(CS-FV)marker vaccine candidate RecC-M1,this experiment employed a double immunization scheme by im-munizing twelve gilts,with RecC-M1 at a dose of 5.0×103.5 TCID50 via intramuscular injection in the neck muscles.Twenty randomly selected gilts from the same farm served as control animals and were immunized with the attenuated C strain vaccine at 750 RID using a conventional immunization program.The experi-mental gilts were observed for clinical symptoms,and their farrowing performance was recorded.Nasal and rectal swab samples were collected on days 3,5,7,and 14 post-primary immunization.Blood samples were collected via tail vein puncture during mid-pregnancy and on the day of farrowing.Viral viremia and shed-ding were determined by quantitative PCR(qPCR),while antibody levels against the corresponding anti-gens for BVDV1(bovine viral diarrhea virus type 1)and CSFV were assessed by indirect ELISA.On the day of parturition,two newborn piglets(a total of 24 piglets)deprived of colostrum were selected from each gilt that received RecC-M1.Post-mortem examinations were conducted to observe gross lesions.Ton-sils,lymphs nodes,spleens,and bladder were sampled for histopathological observations.Blood samples were collected for detection of CSFV antibodies and viral nucleic acids.The results showed that all gilts im-munized with RecC-M1 did not show any clinical symptoms,and were negative of viral nucleic acid in swab samples collected within two weeks post-vaccination.Antibody levels against CSFV E2 and BVDV1-Erns in the sera from gilts remained high during mid-pregnancy and farrowing.There were no significant differ-ences in litter size,stillbirths,or weak piglets between RecC-M1 vaccinated and control gilts.Post-mortem examination revealed that the newborn piglets from RecC-M1-vaccinated gilts did not have any gross path-ological changes in the tonsils,lymph nodes,spleens,kidneys,or bladders.Histological examination showed normal tissue structures in tonsils,lymph nodes,spleens and kidneys with no evidence of hemorrhagic changes.Viral nucleic acid and specific antibody conversion were not detected in the blood and tissue sam-ples from piglets.This study indicated that the attenuated CSFV marker vaccine candidate RecC-M1 is safe for both gilts and piglets,and vertical transmission did not occur,thus providing experimental foundation for its industrial development.

Classical swine feverAttenuated marker vaccineVertical transmission

许翰坤、曹统、王作欢、张鹏超、蓝胜芝、吴桃芬、杨香林、李肖梁、方维焕

展开 >

浙江大学动物预防医学研究所,浙江 杭州 310058

正大集团正大猪业(余姚)有限公司,浙江宁波 315460

浙江诗华诺倍威生物技术有限公司,浙江 杭州 310058

猪瘟 弱毒标记疫苗 垂直传播

2025

动物医学进展
西北农林科技大学

动物医学进展

北大核心
影响因子:0.857
ISSN:1007-5038
年,卷(期):2025.46(1)